TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TherapeuticsMD ( (TXMD) ) has shared an announcement.
On November 12, 2025, TherapeuticsMD announced its financial results for the third quarter of 2025, reporting a net income of $50 thousand, a significant improvement from a net loss of $567 thousand in the same period of 2024. The company also reported an increase in license revenue to $784 thousand, primarily from the Mayne License Agreement, and a slight decrease in operating expenses. As of September 30, 2025, the company’s cash and cash equivalents totaled $7.1 million. TherapeuticsMD is evaluating strategic alternatives, including potential acquisitions or mergers, but has not set a timetable for these explorations.
Spark’s Take on TXMD Stock
According to Spark, TipRanks’ AI Analyst, TXMD is a Neutral.
TherapeuticsMD is undergoing significant challenges, with financial difficulties being the primary concern due to declining revenues and profitability issues. The technical analysis indicates some short-term momentum but struggles over the longer term. Valuation metrics are not attractive, with a negative P/E ratio and no dividend yield. Corporate events provide a glimmer of hope, with reduced losses and strategic initiatives suggesting potential future improvements. However, the overall outlook remains cautious.
To see Spark’s full report on TXMD stock, click here.
More about TherapeuticsMD
TherapeuticsMD, Inc., previously a women’s healthcare company, transitioned in December 2022 to a pharmaceutical royalty company, focusing on collecting royalties from its licensees rather than engaging in research and development or commercial operations.
Average Trading Volume: 188,150
Technical Sentiment Signal: Hold
Current Market Cap: $19.44M
See more insights into TXMD stock on TipRanks’ Stock Analysis page.